The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
Open accessAbstract
Overexpression of FGF receptor 3 (FGFR3) is implicated in the development of t(4;14)-positive multiple myeloma. While FGFR3 is frequently overexpressed and/or activated through mutations in bladder cancer, the functional importance of FGFR3 and its potential as a specific therapeutic target in this disease have not been elucidated in vivo. Here we report that inducible knockdown of FGFR3 in human bladder carcinoma cells arrested cell-cycle progression in culture and markedly attenuated tumor progression in xenografted mice. Further, we developed a unique antibody (R3Mab) that inhibited not only WT FGFR3, but also various mutants of the receptor, including disulfide-linked cysteine mutants. Biochemical analysis and 2.1-A resolution crystallography revealed that R3Mab bound to a specific FGFR3 epitope that simultaneously blocked ligand binding, prevented receptor dimerization, and induced substantial conformational changes in the receptor. R3Mab exerted potent antitumor activity against bladder carcinoma and t(4;14)-positive multiple myeloma xenografts in mice by antagonizing FGFR3 signaling and eliciting antibody-dependent cell-mediated cytotoxicity (ADCC). These studies provide in vivo evidence demonstrating an oncogenic role of FGFR3 in bladder cancer and support antibody-based targeting of FGFR3 in hematologic and epithelial cancers driven by WT or mutant FGFR3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ellman, G. L. (1959) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(59)90090-6 · Cited by 26,311
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Cellular signaling by fibroblast growth factor receptors
Eswarakumar, V. P., Lax, I., & Schlessinger, J. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.001 · Cited by 1,929
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Hudziak, R. M., Lewis, G. D., Winget, M., Fendly, B. M., Shepard, H. M., & Ullrich, A. (1989) · Molecular and Cellular Biology · doi:10.1128/mcb.9.3.1165 · Cited by 749
Structural basis for fibroblast growth factor receptor activation
Mohammadi, M., Olsen, S. K., & Ibrahimi, O. A. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.008 · Cited by 735
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
Cappellen, D., De Oliveira, C., Ricol, D., de Medina, S., Bourdin, J., Sastre-Garau, X., Chopin, D., Thiery, J. P., & Radvanyi, F. (1999) · Nature Genetics · doi:10.1038/12615 · Cited by 713
Clinical and biologic implications of recurrent genomic aberrations in myeloma
Fonseca, R., Blood, E., Rue, M., Harrington, D., Oken, M. M., Kyle, R. A., Dewald, G. W., Van Ness, B., Van Wier, S. A., Henderson, K. J., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3017 · Cited by 660
Mechanisms underlying differential responses to FGF signaling
Dailey, L., Ambrosetti, D., Mansukhani, A., & Basilico, C. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.007 · Cited by 649
Chesi, M., Nardini, E., Brents, L. A., Schröck, E., Ried, T., Kuehl, W. M., & Bergsagel, P. L. (1997) · Nature Genetics · doi:10.1038/ng0797-260 · Cited by 637
Structural Basis for FGF Receptor Dimerization and Activation
Plotnikov, A. N., Schlessinger, J., Hubbard, S. R., & Mohammadi, M. (1999) · Cell · doi:10.1016/s0092-8674(00)80051-3 · Cited by 609
Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy
Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.817 · Cited by 543
Self-citationNaski, M. C., Wang, Q., Xu, J., & Ornitz, D. M. (1996) · Nature Genetics · doi:10.1038/ng0696-233 · Cited by 498
Self-citationMasui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., & Mendelsohn, J. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)50005-1 · Cited by 446
Fibroblast growth factor signaling in tumorigenesis
Grose, R., & Dickson, C. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.003 · Cited by 404
Tomlinson, D., Baldo, O., Harnden, P., & Knowles, M. (2007) · The Journal of Pathology · doi:10.1002/path.2207 · Cited by 363
FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma
Jebar, A. H., Hurst, C. D., Tomlinson, D. C., Johnston, C., Taylor, C. F., & Knowles, M. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208705 · Cited by 340
Moreau, P., Facon, T., Leleu, X., Morineau, N., Huyghe, P., Harousseau, J.-L., Bataille, R., & Avet-Loiseau, H. (2002) · Blood · doi:10.1182/blood-2002-03-0749 · Cited by 317
Chesi, M., Brents, L. A., Ely, S. A., Bais, C., Robbiani, D. F., Mesri, E. A., Kuehl, W. M., & Bergsagel, P. L. (2001) · Blood · doi:10.1182/blood.v97.3.729 · Cited by 289
Trudel, S., Li, Z. H., Wei, E., Wiesmann, M., Chang, H., Chen, C., Reece, D., Heise, C., & Stewart, A. K. (2005) · Blood · doi:10.1182/blood-2004-10-3913 · Cited by 289
Ligand specificity and heparin dependence of fibroblast growth factor receptors 1 and 3.
Ornitz, D. M., & Leder, P. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42001-7 · Cited by 255
Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., SATO, G. H., & Mendelsohn, J. (1984) · PubMed · Cited by 254
Cell responses to FGFR3 signalling: growth, differentiation and apoptosis
L'Hôte, C. G. M., & Knowles, M. A. (2005) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.11.012 · Cited by 218
Olsen, S. K., Ibrahimi, O. A., Raucci, A., Zhang, F., Eliseenkova, A. V., Yayon, A., Basilico, C., Linhardt, R. J., Schlessinger, J., & Mohammadi, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307287101 · Cited by 192
Frequent FGFR3 mutations in urothelial papilloma
van Rhijn, B. W. G., Montironi, R., Zwarthoff, E. C., Jöbsis, A. C., & van der Kwast, T. H. (2002) · The Journal of Pathology · doi:10.1002/path.1202 · Cited by 189
Plowright, E. E., Li, Z., Bergsagel, P. L., Chesi, M., Barber, D. L., Branch, D. R., Hawley, R. G., & Stewart, A. K. (2000) · Blood · doi:10.1182/blood.v95.3.992.003k29_992_998 · Cited by 165
Trudel, S., Ely, S., Farooqi, Y., Affer, M., Robbiani, D. F., Chesi, M., & Bergsagel, P. L. (2004) · Blood · doi:10.1182/blood-2003-10-3650 · Cited by 162
Targeting FGFR3 in multiple myeloma: inhibition of t(4;14)-positive cells by SU5402 and PD173074
Grand, E., Chase, A., Heath, C., Rahemtulla, A., & Cross, N. (2004) · Leukemia · doi:10.1038/sj.leu.2403347 · Cited by 158
Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b
Bernard‐Pierrot, I., Brams, A., Dunois-Lardé, C., Caillault, A., de Medina, S. G. D., Cappellen, D., Graff, G., Thiery, J. P., Chopin, D. K., Ricol, D., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi290 · Cited by 157
Smoking and cancer‐related gene expression in bronchial epithelium and non‐small‐cell lung cancers
Woenckhaus, M., Klein‐Hitpaß, L., Grepmeier, U., Merk, J., Pfeifer, R., Wild, P. J., Bettstetter, M., Wuensch, P. H., Blaszyk, H., Hartmann, A., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2039 · Cited by 153
The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells
Trudel, S., Stewart, A. K., Rom, E., Wei, E. N., Li, Z. H., Kotzer, S., Chumakov, I., Singer, Y., Chang, H., Liang, S., et al. (2006) · Blood · doi:10.1182/blood-2005-10-4179 · Cited by 143
Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer
Tomlinson, D. C., Hurst, C. D., & Knowles, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210399 · Cited by 128
Ronchetti, D., Greco, A., Compasso, S., Colombo, G., Dell'Era, P., Otsuki, T., Lombardi, L., & Neri, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204465 · Cited by 119
Martínez-Torrecuadrada, J., Cifuentes, G., Lopez-Serra, P., Sáenz, P., Martínez, A., & Casal, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0282 · Cited by 118
Li, Z.-H., Zhu, Y.-X., Plowright, E. E., Bergsagel, P., Chesi, M., Patterson, B., Hawley, T., Hawley, R. G., & Stewart, A. K. (2001) · Blood · doi:10.1182/blood.v97.8.2413 · Cited by 100
NMDA receptor redox sites: are they targets for selective neuronal protection?
GOZLAN, H. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)89077-x · Cited by 92
FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies
Chen, J., Lee, B. H., Williams, I. R., Kutok, J. L., Mitsiades, C. S., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R. O., Coburn, A., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208989 · Cited by 92
Agazie, Y. M., Movilla, N., Ischenko, I., & Hayman, M. J. (2003) · Oncogene · doi:10.1038/sj.onc.1206798 · Cited by 88
Paterson, J., Li, Z.-H., Wen, X., Masih-Khan, E., Chang, H., Pollett, J. B., Trudel, S., & Stewart, A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.04814.x · Cited by 87
Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma
Chang, H., Stewart, A. K., Qi, X. Y., Li, Z., Yi, Q. L., & Trudel, S. (2005) · Blood · doi:10.1182/blood-2005-01-0033 · Cited by 77
Adar, R., Ornan, E. M., David, P., & Yayon, A. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.5.860 · Cited by 75
d'AVIS, P. Y., Robertson, S., Meyer, A. L., Bardwell, W., Webster, M. K., & Donoghue, D. J. (1998) · PubMed · Cited by 72
Novel Therapeutic Targets In Bladder Cancer: Mutation and Expression of Fgf Receptors
Knowles, M. A. (2008) · Future Oncology · doi:10.2217/14796694.4.1.71 · Cited by 69
Xin, X., Abrams, T. J., Hollenbach, P. W., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0957 · Cited by 66
Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma
Qiu, W.-H. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i34.5266 · Cited by 60
Pollett, J. B., Trudel, S., Stern, D., Li, Z.-X., & Stewart, A. K. (2002) · Blood · doi:10.1182/blood-2002-02-0608 · Cited by 51
Chen, J., Williams, I., Lee, B. H., Duclos, N., Huntly, B. J. P., Donoghue, D. J., & Gilliland, D. G. (2004) · Blood · doi:10.1182/blood-2004-09-3686 · Cited by 41
Martinez-Torrecuadrada, J. L., Cheung, L. H., López-Serra, P., Barderas, R., Cañamero, M., Ferreiro, S., Rosenblum, M. G., & Casal, J. I. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0394 · Cited by 37
Cited by
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
The Fibroblast Growth Factor signaling pathway
Ornitz, D. M., & Itoh, N. (2015) · WIREs Developmental Biology · doi:10.1002/wdev.176 · Cited by 2,050
FGF Receptors: Cancer Biology and Therapeutics: CANCER BIOLOGY AND THERAPEUTICS ON FGF RECEPTORS
Katoh, M., & Nakagama, H. (2014) · Medicinal Research Reviews · doi:10.1002/med.21288 · Cited by 610
Fibroblast growth factors and their receptors in cancer
Wesche, J., Haglund, K., & Haugsten, E. M. (2011) · Biochemical Journal · doi:10.1042/bj20101603 · Cited by 534
Targeting FGFR Signaling in Cancer
Touat, M., Ileana, E., Postel-Vinay, S., André, F., & Soria, J.-C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2329 · Cited by 524
Metadata
- Authors
- Qing, J., Du, X., Chen, Y., Chan, P., Li, H., Wu, P., Marsters, S., Stawicki, S., Tien, J., Totpal, K., Ross, S., Stinson, S., Dornan, D., French, D., Wang, Q.-R., Stephan, J.-P., Wu, Y., Wiesmann, C., & Ashkenazi, A.
- Venue
- Journal of Clinical Investigation
- Published
- 2009-05-01
- Volume
- 119
- Issue
- 5
- Pages
- 1216-1229
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2143895308
- Cited by
- 255
- References
- 48
- FWCI
- 9.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.